TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1974399

Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 883006

Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 114
Study: 31305251

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 28426856

Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 26109580

Group type: EXPERIMENTAL
Intervention: Active implicit priming (n = 22) with high-calorie food images paired with negatively valenced images and low-calorie food images paired with positively valenced images.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control implicit priming (n = 20) with all food images primed with neutral images.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active implicit priming (n = 22)
Number of subjects: 42
Study: 24193286

Group type: EXPERIMENTAL
Intervention: PPH
Number of subjects: 122

Group type: COMPARATOR
Intervention: THD
Number of subjects: 122
Study: 21991809

Group type: EXPERIMENTAL
Intervention: rhGMCSF gel
Number of subjects: 58

Group type: COMPARATOR
Intervention: gel matrix (control group)
Number of subjects: 58
Study: 19522050

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 60
Study: 17270384

Group type: EXPERIMENTAL
Intervention: Risk factor tested (which may be a drug) in case-control studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure in cohort studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 0
Study: 16225715

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation with pressure set at 15 cmH2O (Group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Spontaneous breathing (Group 2)
Number of subjects: 35
Study: 16200777

Group type: EXPERIMENTAL
Intervention: Single dose of rhTPO at doses of 0.25, 0.5, 1.0, and 2.0 microg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Multiple dose of rhTPO at 1.0 microg/kg for 7 - 14 days
Number of subjects: 34
Study: 9395007

Group type: EXPERIMENTAL
Intervention: Lodoxamide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Spaglumic acid
Number of subjects: 32
Study: 8204192

Group type: EXPERIMENTAL
Intervention: ADAS cognitive score
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Mental status factor score
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Verbal fluency factor score
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Praxis factor score
Number of subjects: 280
Study: 2958950

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 micrograms three times a day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31691352

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Water and liquid baby cleanser
Number of subjects: 100
Study: 29282650

Group type: EXPERIMENTAL
Intervention: Supported employment intervention
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 283
Study: 28802593

Group type: EXPERIMENTAL
Intervention: QLB group (posterior quadratus lumborum block with 20mL of 0.375% ropivacaine on each side)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: QLB group
Number of subjects: 70
Study: 26291137

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg
Number of subjects: 1039

Group type: COMPARATOR
Intervention: FF 100 mcg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 mcg
Number of subjects: 1039
Study: 23072366

Group type: EXPERIMENTAL
Intervention: Resin-based sealant
Number of subjects: 276

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 276
Study: 21966478

Group type: EXPERIMENTAL
Intervention: Short-term visual deprivation
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Repeated testing
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 158
Study: 18508207

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 16572425

Group type: EXPERIMENTAL
Intervention: HPV testing (Hybrid Capture 2)
Number of subjects: 9667

Group type: COMPARATOR
Intervention: Pap cytology (conventional)
Number of subjects: 9667

Group type: EXPERIMENTAL
Intervention: Both tests (HPV and Pap)
Number of subjects: 9667
Study: 14520777

Group type: EXPERIMENTAL
Intervention: elmex interX medium toothbrush
Number of subjects: 112

Group type: COMPARATOR
Intervention: ADA‐Accepted flat‐bristle profile toothbrush
Number of subjects: 112
Study: 11308437

Group type: EXPERIMENTAL
Intervention: Flow diagrams included in reports of RCTs
Number of subjects: 270
Study: 9161310

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 179
Study: 7838417

Group type: EXPERIMENTAL
Intervention: beta‐IFN therapy at a dose of 300,000 UI/die i.m. for 7 days, continuing the same dose on alternate days for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group of 9 patients
Number of subjects: 10
Study: 3283097

Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg single dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 200
Study: 31395418

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100000 epinephrine
Number of subjects: 90
Study: 28549983

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 851

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study: 25863422

Group type: EXPERIMENTAL
Intervention: BNP rise group (334 patients)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: BNP decrease or no change group (599 patients)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Overall group (1,097 patients)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Moderate or severe aortic regurgitation
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Increase in BNP at 30 days
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons score
Number of subjects: 1097
Study: 23906646

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administered to the parent
Number of subjects: 35
Study: 21538340

Group type: EXPERIMENTAL
Intervention: Single-port cholecystectomy (SPC)
Number of subjects: 49
Study: 19664250

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization (EPI)
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Single dose infant formulations of IPTi
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Newer drugs used in IPTi
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Routine vaccination (EPI)
Number of subjects: 1296
Study: 17045409

Group type: EXPERIMENTAL
Intervention: Citalopram IV infusion (20 mg over 120 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 16145914

Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate with 5‐fluorouracil (5‐FU)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Contrast medium without 5‐fluorouracil (5‐FU)
Number of subjects: 160
Study: 11148810

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90
Study: 8765270

Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (direct labor induction)
Number of subjects: 79
Study: 1577936

Group type: EXPERIMENTAL
Intervention: Slow release intrauterine insemination (treatment A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bolus intrauterine insemination (treatment B)
Number of subjects: 38
Study: 3899669

Group type: EXPERIMENTAL
Intervention: Pinacidil alone (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HCTZ/amiloride (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HCTZ and amiloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pinacidil added to HCTZ/amiloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phases 1 and 2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phase 2
Number of subjects: 30
Study: 30997650

Group type: EXPERIMENTAL
Intervention: Optimal Sampling Strategy (OSS) using time points of 2, 4, and 8 hours post-dose for first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External validation of OSS
Number of subjects: 0
Study: 29266340

Group type: EXPERIMENTAL
Intervention: Advisory brochure on fish consumption guidelines
Number of subjects: 0
Study: 26891645

Group type: EXPERIMENTAL
Intervention: Pilates sessions in addition to conventional treatment with occlusal splint
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment with occlusal splint
Number of subjects: 40
Study: 24962042

Group type: EXPERIMENTAL
Intervention: Group A: 4 screws and a 4‐hole miniplate for internal fixation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B: 3 screws (only 1 screw in the proximal segment) and a 4‐hole miniplate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 30
Study: 22437411

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin (13-15 g/dl)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Lower hemoglobin (9-11 g/dl)
Number of subjects: 1265
Study: 20103685

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 527
Study: 18271233

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) warming therapy combined with oral administration of Pyridostigmine (90 ‐ 240 mg each day) and Prednisone (30 ‐ 60 mg each day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Pyridostigmine (240‐480 mg each day) and Prednisone (60‐100 mg each day)
Number of subjects: 60
Study: 16279900

Group type: EXPERIMENTAL
Intervention: PEG IFN alpha‐2b 1.5 microg/kg per wk plus RBV 800 mg per day (Regimen A)
Number of subjects: 321

Group type: COMPARATOR
Intervention: PEG IFN alpha‐2b 1.0 microg/kg per wk plus RBV 1,000‐1,200 mg per day (Regimen B)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Combination therapy nonresponders
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: IFN monotherapy nonresponders
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Combination therapy relapsers
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: HCV ribonucleic acid levels <100,000 copies/mL
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Genotype 1 patients
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 321
Study: 11872551

Group type: EXPERIMENTAL
Intervention: Homoeopathic immunotherapy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 10195529

Group type: EXPERIMENTAL
Intervention: 10 mL of bupivacaine 0.25%
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 mL of saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5 mL of bupivacaine 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5 mL of saline
Number of subjects: 50

Group type: COMPARATOR
Intervention: No epidural top-up
Number of subjects: 50
Study: 9626172

Group type: EXPERIMENTAL
Intervention: L-arginine (3 g TID for 6 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1770314

Group type: EXPERIMENTAL
Intervention: D-alpha-tocopherol (vitamin E) supplementation at dosages of 150, 225, 800, or 1200 IU for 21 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6126441

Group type: EXPERIMENTAL
Intervention: 200 mg diacetolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 400 mg diacetolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 600 mg diacetolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30987457

Group type: EXPERIMENTAL
Intervention: BOOSTTM midsole materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional materials
Number of subjects: 0
Study: 30233159

Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/day) with meloxicam (Mlx)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Meloxicam (Mlx) alone
Number of subjects: 110
Study: 26818756

Group type: EXPERIMENTAL
Intervention: Muscle vibration treatment at 200 Hz
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Muscle vibration treatment at 100 Hz
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study: 24818764

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Low-dosage EPA-E (1800 mg/d)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: High-dosage EPA-E (2700 mg/d)
Number of subjects: 243
Study: 22639399

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (1 hour twice a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Counseling on the risk of diabetes and its prevention
Number of subjects: 60
Study: 20137766

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin (FPNS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fentanyl chitosan (FChNS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fentanyl in chitosan-poloxamer 188 (FChPNS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 18
Study: 18613959

Group type: EXPERIMENTAL
Intervention: 1-year group behavioral program based on Self-Determination Theory (SDT) with 30 sessions of 2 hours each, delivered weekly or bi-weekly.
Number of subjects: 0

Group type: COMPARATOR
Intervention: General health education curriculum.
Number of subjects: 0
Study: 15966958

Group type: EXPERIMENTAL
Intervention: Assertive outreach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 30
Study: 11818200

Group type: EXPERIMENTAL
Intervention: CEF14 (chemotherapy every 14 days)
Number of subjects: 392

Group type: COMPARATOR
Intervention: CEF21 (chemotherapy every 21 days)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: CEF14
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 392
Study: 9880419

Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin implant plus metronidazole 20 to 40 mg/kg/day IV for 7 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Open wounds treated with local cleansing, metronidazole 20 to 40 mg/kg/day IV and gentamicin 5 mg/kg/day IV for 7 days
Number of subjects: 73
Study: 7722116

Group type: EXPERIMENTAL
Intervention: Ambulatory training program
Number of subjects: 22
Study: 2024227

Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin, gentamicin and clindamycin (standard therapy)
Number of subjects: 0
Study: 7270476

Group type: EXPERIMENTAL
Intervention: Fasting (skipping breakfast)
Number of subjects: 0
Study: 31561651

Group type: EXPERIMENTAL
Intervention: Regional anesthesia without sedation
Number of subjects: 57

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 57
Study: 27179664

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 103
Study: 25470476

Group type: EXPERIMENTAL
Intervention: Guided imagery group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study: 23339538

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure with Cognitive Restructuring (PE/CR)
Number of subjects: 153
Study: 21366805

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 8 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 20129385

Group type: EXPERIMENTAL
Intervention: Fibrinogen‐LDL‐apheresis
Number of subjects: 200
Study: 17507306

Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus one of the new ritonavir‐boosted protease inhibitors (tipranavir or darunavir) and an optimised background treatment regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 0
Study: 15501375

Group type: EXPERIMENTAL
Intervention: Motivated Stepped Care (MSC) with behavioral contingencies
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard Stepped Care (SSC) without behavioral contingencies
Number of subjects: 127
Study: 11470622

Group type: EXPERIMENTAL
Intervention: Pen-based interface
Number of subjects: 0

Group type: COMPARATOR
Intervention: Keyboard interface
Number of subjects: 0
Study: 10068730

Group type: EXPERIMENTAL
Intervention: Triple regimen PAC (pantoprazole 40 mg bid, clarithromycin 500 mg tid, amoxicillin 1 g bid)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dual regimen PC (pantoprazole, clarithromycin, placebo)
Number of subjects: 74
Study: 7993327

Group type: EXPERIMENTAL
Intervention: Suppression of thoughts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thinking about thoughts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recording thoughts
Number of subjects: 0
Study: 2178870

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 50 mg diclofenac twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 24
Study: 88710

Group type: EXPERIMENTAL
Intervention: Hydromorphone (narcotic) delivered in a demand analgesia (DA) system, dosage varied in response to patient-triggered apparatus.
Number of subjects: 34
Study: 31006941

Group type: EXPERIMENTAL
Intervention: Diabetes Benefit Finding Scale for Parents (DBFS-P)
Number of subjects: 172
Study: 27868359

Group type: EXPERIMENTAL
Intervention: Linagliptin add-on group (linagliptin 5 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Metformin group (1,500 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (metformin 750 mg/day)
Number of subjects: 96
Study: 25891223

Group type: EXPERIMENTAL
Intervention: Autograft (gracilis and semitendinosus tendons)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hybrid graft (γ‐irradiated tibialis anterior tendon allograft and semitendinosus tendon autograft)
Number of subjects: 102

Group type: COMPARATOR
Intervention: γ‐irradiated allograft (tibialis anterior tendons)
Number of subjects: 102
Study: 23830727

Group type: EXPERIMENTAL
Intervention: Culturally sensitive structured education programme (CSSEP)
Number of subjects: 430
Study: 21312345

Group type: EXPERIMENTAL
Intervention: Pain-avoidance treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain-persistence treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain-avoidance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain-persistence treatment
Number of subjects: 0
Study: 19058896

Group type: EXPERIMENTAL
Intervention: Basic life support‐defibrillation (BLS‐D) training
Number of subjects: 52

Group type: COMPARATOR
Intervention: No previous BLS‐D training with dispatcher assistance
Number of subjects: 52
Study: 17366335

Group type: EXPERIMENTAL
Intervention: Persuasive educational mailing intervention
Number of subjects: 8499

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 8499
Study: 15583226

Group type: EXPERIMENTAL
Intervention: 2 days of sleep restriction
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 days of sleep extension
Number of subjects: 12
Study: 11484963

Group type: EXPERIMENTAL
Intervention: Vinorelbine at 25 mg/m2 weekly for at least eight weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 47
Study: 9552027

Group type: EXPERIMENTAL
Intervention: VIP (etoposide, ifosfamide, and cisplatin)
Number of subjects: 304

Group type: COMPARATOR
Intervention: BEP (bleomycin, etoposide, and cisplatin)
Number of subjects: 304
Study: 7920274

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of one gram of Ambroxol in 500 ml of 0.9% saline daily for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group received infusions of 500 ml 0.9% saline at the same intervals
Number of subjects: 20
Study: 2968248

Group type: EXPERIMENTAL
Intervention: Immediate PTCA after thrombolysis
Number of subjects: 533

Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 533
Study: 1093947

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Selective vagotomy with pyloroplasty
Number of subjects: 100
Study: 31302020

Group type: EXPERIMENTAL
Intervention: Mentari health education
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 28612897

Group type: EXPERIMENTAL
Intervention: Italian version of the WHO questionnaire on Workplace Violence in the Health Sector
Number of subjects: 55
Study: 25413366

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AngII) infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACTH infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-salt diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 60